Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors

Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), although initially developed as glucose-lowering drugs, provide significant beneficial effects on cardiorenal outcomes, including heart failure, regardless of type 2 diabetes status...

Full description

Bibliographic Details
Main Authors: Serge A. Jabbour, Nasrien E. Ibrahim, Christos P. Argyropoulos
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Journal of Clinical Medicine
Subjects:
sodium-glucose cotransporter-2 inhibitors
cardiovascular
renal
safety
type 2 diabetes
Online Access:https://www.mdpi.com/2077-0383/11/20/6051

Similar Items

Similar Items